ImmunoGen, Inc. To Ring The NASDAQ Stock Market Closing Bell

ADVISORY, April 1, 2013 (GLOBE NEWSWIRE) --

What:

ImmunoGen, Inc. [IMGN], a developer of targeted anticancer therapeutics, will visit the NASDAQ MarketSite in Times Square.

In honor of the occasion, Daniel Junius, President and CEO, will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio

When:

Tuesday, April 2, 2013 – 3:45 p.m. to 4:00 p.m. ET

Contact : Sarah Cue (781) 895-0835 Mobile: (508) 320-3258 Sarah.cue@immunogen.com

NASDAQ MarketSite: Jen Knapp (212) 401-8916 Jennifer.knapp@nasdaqomx.com

Feed Information: Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at: http://www.facebook.com/NASDAQ .

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx .

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx .

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About ImmunoGen, Inc. [IMGN]:

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer-killing agents specifically to tumor cells. Ten TAP compounds are now in clinical testing, of which three are wholly owned by the Company. ImmunoGen expects to advance its fourth wholly owned compound into clinical testing later this year. The most advanced compound using ImmunoGen's TAP technology, Kadcyla (formerly T-DM1) has been approved for marketing in the U.S. and is undergoing regulatory review in Europe and Japan; it is being commercialized in the U.S. by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com .

About NASDAQ OMX Group:

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com . Follow us on Facebook ( http://www.facebook.com/NASDAQ ) and Twitter ( http://www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)

-NDAQA-

If you liked this article you might like

Walt Disney, Tiffany, NASDAQ, Mazor Robotics: 'Mad Money' Lightning Round

A Ferocious Rotation: Cramer's 'Mad Money' Recap (Friday 6/9/17)

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

The Stock Market Has Been Amazingly Resilient -- Check Out These 10 Charts